Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2006 3
2007 4
2008 1
2009 2
2010 3
2011 2
2012 4
2013 1
2014 3
2015 2
2016 4
2017 2
2018 3
2019 6
2020 1
2021 2
2022 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H, Brown Z, Burns A, Williams T. Barnes H, et al. Cochrane Database Syst Rev. 2019 Jan 31;1(1):CD012621. doi: 10.1002/14651858.CD012621.pub2. Cochrane Database Syst Rev. 2019. PMID: 30701543 Free PMC article.
BACKGROUND: Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated pulmonary artery pressure, and which left untreated leads to right-heart failure and death. ...There were limited trials comparing PDE5 …
BACKGROUND: Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated …
Tadalafil therapy for pulmonary arterial hypertension.
Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Galiè N, et al. Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Circulation. 2009. PMID: 19470885 Clinical Trial.
BACKGROUND: Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. ...METHODS AND RESULTS: In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hy …
BACKGROUND: Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide …
Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.
Kirtania L, Maiti R, Srinivasan A, Mishra A. Kirtania L, et al. Clin Drug Investig. 2019 Nov;39(11):1031-1044. doi: 10.1007/s40261-019-00841-1. Clin Drug Investig. 2019. PMID: 31420854
BACKGROUND: The combination of an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor having different biological targets has become an integral part of the treatment of pulmonary arterial hypertension; howeve …
BACKGROUND: The combination of an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor …
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N. Tapson VF, et al. Chest. 2012 Dec;142(6):1383-1390. doi: 10.1378/chest.11-2212. Chest. 2012. PMID: 22628490 Clinical Trial.
BACKGROUND: Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their administration routes have limitations. This study assessed the efficacy and safety of bid oral sustained-release treprostinil in the tr …
BACKGROUND: Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although th …
[Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
Fu WH, Chen PL, Xia JL, Fu L, Shen Y, He WJ, Chen YH, Ren N, Jiang Q, Ma R, Wang T, Wang XN, Zhang NF, Liu CL. Fu WH, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2022 Feb 12;45(2):158-170. doi: 10.3760/cma.j.cn112147-20210707-00473. Zhonghua Jie He He Hu Xi Za Zhi. 2022. PMID: 35135085 Chinese.
Objective: To examine the efficacy and safety of endothelin receptor antagonists (ERA) combined with phosphodiesterase 5 inhibitors (PDE5i) in the treatment of pulmonary artery hypertension (PAH). Methods: Computer-based ret …
Objective: To examine the efficacy and safety of endothelin receptor antagonists (ERA) combined with phosphodiestera …
Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: A network meta-analysis.
Lin H, Wang M, Yu Y, Qin Z, Zhong X, Ma J, Zhao F, Zhang X. Lin H, et al. Pulm Pharmacol Ther. 2018 Jun;50:1-10. doi: 10.1016/j.pupt.2017.11.002. Epub 2017 Nov 8. Pulm Pharmacol Ther. 2018. PMID: 29128622
PURPOSE: This network meta-analysis (NMA) is designed to compare the efficacy and tolerability of various therapies and combinations for pulmonary arterial hypertension (PAH). METHOD: We conducted a systematic search in databases PubMed, Embase, and Cochrane Library …
PURPOSE: This network meta-analysis (NMA) is designed to compare the efficacy and tolerability of various therapies and combinations for …
Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension.
Savarese G, Musella F, D'Amore C, Losco T, Marciano C, Gargiulo P, Rengo G, Dellegrottaglie S, Bossone E, Leosco D, Perrone-Filardi P. Savarese G, et al. Eur Respir J. 2013 Aug;42(2):414-24. doi: 10.1183/09031936.00123712. Epub 2012 Oct 25. Eur Respir J. 2013. PMID: 23100502 Free article.
No relationship was found between changes of haemodynamic parameters and clinical events, whereas changes of cardiac index and pulmonary vascular resistance significantly correlated with changes in the 6-min walking distance (r = 0.64, p = 0.03; r = -0.55, p …
No relationship was found between changes of haemodynamic parameters and clinical events, whereas changes of cardiac index and pulmonary …
Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension.
Sun H, Stockbridge N, Ariagno RL, Murphy D, Nelson RM, Rodriguez W. Sun H, et al. J Perinatol. 2016 Dec;36(12):1029-1033. doi: 10.1038/jp.2016.103. Epub 2016 Jul 14. J Perinatol. 2016. PMID: 27416322 Free PMC article. Review.
OBJECTIVE: To identify suitable end points and surrogates for pediatric pulmonary arterial hypertension (PAH) as the lack of developmentally appropriate end point and clinical trials contribute to the unmet medical need. ...However, two deaths and three severe adver …
OBJECTIVE: To identify suitable end points and surrogates for pediatric pulmonary arterial hypertension (PAH) as the lack of d …
Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial.
Chang HJ, Song S, Chang SA, Kim HK, Jung HO, Choi JH, Lee JS, Kim KH, Jeong JO, Lee JH, Kim DK. Chang HJ, et al. Clin Ther. 2019 Aug;41(8):1499-1507. doi: 10.1016/j.clinthera.2019.05.006. Epub 2019 Jun 13. Clin Ther. 2019. PMID: 31202506 Clinical Trial.
PURPOSE: Udenafil is an oral phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. ...Among the patients with a history of endothelin receptor antagonist therapy, the treatment effect at week 16 between the ude …
PURPOSE: Udenafil is an oral phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. ...Among …
Emerging medical therapies for pulmonary arterial hypertension.
Galiè N, Manes A, Branzi A. Galiè N, et al. Prog Cardiovasc Dis. 2002 Nov-Dec;45(3):213-24. doi: 10.1053/pcad.2002.130160. Prog Cardiovasc Dis. 2002. PMID: 12525997 Review.
Until a few years ago, "conventional" treatment for pulmonary arterial hypertension (PAH) included oral anticoagulants, calcium channel blockers, diuretics, digoxin, and oxygen. ...Recently, the thromboxane inhibitor terbogrel, the prostacyclin analogues treprostini …
Until a few years ago, "conventional" treatment for pulmonary arterial hypertension (PAH) included oral anticoagulants, calciu …
41 results